Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The development of antibody-IL-2 based immunotherapy with hu14 18-IL2 (EMD-273063) in melanoma and neuroblastoma Yamane BH; Hank JA; Albertini MR; Sondel PMExpert Opin Investig Drugs 2009[Jul]; 18 (7): 991-1000Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate adjuvant therapies. Immunotherapy with the immunocytokine hu14.18-IL2 (EMD-273063) was developed by means of fusion of two molecules of IL-2 to the monoclonal antibody, 14.18, that recognizes GD2, expressed on the earlier mentioned malignancies. This article will discuss the results of preclinical work using EMD-273063 therapy, including data suggesting that intratumoral therapy may have enhanced antitumor benefit compared with intravenous therapy. Initial clinical trials in adult melanoma and pediatric neuroblastoma have demonstrated acceptable toxicity profiles in dosing that induces immune activation. Preclinical and initial clinical data suggest greater efficacy in the setting of minimal residual disease; therefore, future clinical testing is planned to test the benefit of EMD-273063 in this setting.|Adult[MESH]|Aged[MESH]|Animals[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Female[MESH]|Humans[MESH]|Immunization, Passive/methods/*trends[MESH]|Interleukin-2/*immunology/therapeutic use[MESH]|Male[MESH]|Melanoma/*immunology/*therapy[MESH]|Middle Aged[MESH]|Neuroblastoma/*immunology/*therapy[MESH] |
